These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 18688848

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
    Magrath I, Shanta V, Advani S, Adde M, Arya LS, Banavali S, Bhargava M, Bhatia K, Gutiérrez M, Liewehr D, Pai S, Sagar TG, Venzon D, Raina V.
    Eur J Cancer; 2005 Jul; 41(11):1570-83. PubMed ID: 16026693
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF, PETHEMA Group, Spanish Society of Hematology.
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [Abstract] [Full Text] [Related]

  • 4. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM, Oren H, Baytan B, Bengoa SY, Evim MS, Gözmen S, Tüfekçi O, Karapınar TH, Irken G.
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [Abstract] [Full Text] [Related]

  • 5. Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience.
    Hazar V, Karasu GT, Uygun V, Akcan M, Küpesiz A, Yesilipek A.
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):e317-22. PubMed ID: 20930649
    [Abstract] [Full Text] [Related]

  • 6. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig WD, Riehm H, Schrappe M.
    Klin Padiatr; 2005 Nov; 217(6):310-20. PubMed ID: 16307416
    [Abstract] [Full Text] [Related]

  • 7. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.
    Boissel N, Auclerc MF, Lhéritier V, Perel Y, Thomas X, Leblanc T, Rousselot P, Cayuela JM, Gabert J, Fegueux N, Piguet C, Huguet-Rigal F, Berthou C, Boiron JM, Pautas C, Michel G, Fière D, Leverger G, Dombret H, Baruchel A.
    J Clin Oncol; 2003 Mar 01; 21(5):774-80. PubMed ID: 12610173
    [Abstract] [Full Text] [Related]

  • 8. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
    Consolini R, Legitimo A, Rondelli R, Guguelmi C, Barisone E, Lippi A, Cantù-Rajnoldi A, Aricò M, Conter V, Cocito MG, Putti MC, Pession A, Masera G, Biondi A, Basso G.
    Haematologica; 1998 Nov 01; 83(11):967-73. PubMed ID: 9864914
    [Abstract] [Full Text] [Related]

  • 9. Treatment of childhood acute lymphoblastic leukaemia with the BFM regimen.
    Kudva GC, Chandy M, Raghupathy P, Dennison D, Srivastava A, Bhushan V, Singh R.
    Indian J Cancer; 1994 Jun 01; 31(2):78-85. PubMed ID: 7927453
    [Abstract] [Full Text] [Related]

  • 10. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A, Ohara A, Hasegawa D, Koh K, Saito T, Kiyokawa N, Kikuchi A, Takahashi H, Ikuta K, Hayashi Y, Hanada R, Tsuchida M, Tokyo Children's Cancer Study Group.
    Haematologica; 2008 Aug 01; 93(8):1155-60. PubMed ID: 18519521
    [Abstract] [Full Text] [Related]

  • 11. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
    Skoczeń S, Balwierz W, Moryl-Bujakowska A, Pawińska K, Luszczyńska A, Balcerska A, Płoszyńska A, Chybicka A, Dobaczewski G, Juszczak K, Wachowiak J, Derwich K, Kowalczyk J, Wiśniewska-Slusarz H, Matysiak M, Krauze A, Pawelec K, Sońta-Jakimczyk D, Tomaszewska R, Wysocki M, Styczyńskii J, Swiatkiewicz V, Polish Pediatric Leukemia/Lymphoma Study Group.
    Przegl Lek; 2006 Aug 01; 63(1):11-4. PubMed ID: 16892892
    [Abstract] [Full Text] [Related]

  • 12. [Treatment of infantile acute lymphoblastic leukemia with protocol ALL-BFM 83].
    Aracil Santos FJ, Bernacer Borja M, López Pérez J, Melero Moreno C, Valverde Moreno F, Gil Gil C, Contra Gómez T, Martín Ramos N.
    An Esp Pediatr; 1989 Oct 01; 31(4):362-7. PubMed ID: 2627059
    [Abstract] [Full Text] [Related]

  • 13. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
    Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Körholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, Kaspers GJ, Kamps WA, Van der Does-Van den Berg A, Van Wering ER, Veerman AJ, Janka-Schaub GE.
    J Clin Oncol; 2003 Sep 01; 21(17):3262-8. PubMed ID: 12947061
    [Abstract] [Full Text] [Related]

  • 14. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
    Rivera GK, Zhou Y, Hancock ML, Gajjar A, Rubnitz J, Ribeiro RC, Sandlund JT, Hudson M, Relling M, Evans WE, Pui CH.
    Cancer; 2005 Jan 15; 103(2):368-76. PubMed ID: 15599932
    [Abstract] [Full Text] [Related]

  • 15. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
    Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M.
    J Clin Oncol; 2006 Dec 20; 24(36):5742-9. PubMed ID: 17179108
    [Abstract] [Full Text] [Related]

  • 16. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, van Wering ER, Lo Nigro L, van der Does A, Locatelli F, Basso G, Aricò M.
    J Clin Oncol; 2005 Oct 01; 23(28):7161-7. PubMed ID: 16192600
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy.
    Reaman GH, Steinherz PG, Gaynon PS, Bleyer WA, Finklestein JZ, Evans R, Miller DR, Sather HN, Hammond GD.
    Cancer Treat Rep; 1987 Nov 01; 71(11):1033-8. PubMed ID: 3315194
    [Abstract] [Full Text] [Related]

  • 19. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.
    Yetgin S, Tuncer MA, Cetin M, Gümrük F, Yenicesu I, Tunç B, Oner AF, Toksoy H, Koç A, Aslan D, Ozyürek E, Olcay L, Atahan L, Tunçbilek E, Gürgey A.
    Leukemia; 2003 Feb 01; 17(2):328-33. PubMed ID: 12592331
    [Abstract] [Full Text] [Related]

  • 20. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
    Attarbaschi A, Mann G, Dworzak M, Urban C, Fink FM, Dieckmann K, Riehm H, Gadner H, Austrian Cooperative Study Group.
    Wien Klin Wochenschr; 2002 Feb 28; 114(4):148-57. PubMed ID: 12060981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.